TLDR
- Moderna has reached a $950 million upfront settlement agreement with Arbutus Biopharma and Genevant Sciences, resolving patent litigation concerning its COVID vaccine technology.
- An additional $1.3 billion payment may be required within 90 days should Moderna lose its ongoing federal appeal.
- This agreement represents the biggest patent settlement in pharmaceutical industry history and ranks second among all sectors.
- Following the settlement announcement, Moderna’s shares surged 8.7% to $54.15 during after-hours trading.
- The company projects cash reserves of $4.5–$5 billion by the close of 2026, with overall liquidity reaching up to $5.9 billion.
A protracted patent battle that has shadowed Moderna for years has reached its conclusion — and investors responded with enthusiasm.
The biotech firm disclosed Tuesday evening that it has agreed to a $950 million lump-sum settlement with Arbutus Biopharma (ABUS) and Genevant Sciences, a private company, effectively ending all worldwide patent disputes related to its Spikevax and mResvia vaccine products.
The litigation revolved around lipid nanoparticle (LNP) delivery systems, a crucial technology for transporting mRNA into cells. Both Arbutus and Genevant alleged that Moderna had utilized their proprietary LNP technology without obtaining proper authorization.
Shares of Arbutus declined 11% to $4.20 during after-hours trading following the settlement disclosure.
The $950 million settlement will be recognized as an expense in the first quarter of 2026, with payment scheduled for the third quarter. Following this one-time payment, Moderna will have no ongoing royalty obligations.
However, there remains a conditional element. Moderna has an active appeal before a federal circuit court, contending it has limited liability as a government contractor. Should the company lose this appeal, it has committed to paying up to $1.3 billion more within a 90-day window.
The maximum potential settlement of $2.25 billion falls significantly short of worst-case scenarios. William Blair analysts noted that market participants had been preparing for potential liabilities approaching $5 billion, which could have triggered substantial liquidity challenges.
Under the settlement terms, Genevant is providing Moderna with a worldwide non-exclusive license to utilize its LNP delivery platform for specific mRNA vaccine applications. Genevant has also committed to refraining from future patent litigation against Moderna concerning certain intellectual property.
What This Means for Moderna’s Cash Position
Factoring in the settlement payment, Moderna anticipates finishing 2026 with cash and cash equivalents between $4.5 billion and $5 billion. The company maintains access to a $900 million credit line, pushing total expected liquidity to a range of $5.4 billion to $5.9 billion.
CEO Stéphane Bancel stated that this agreement eliminates uncertainty and allows the organization to concentrate on future objectives.
Bancel anticipates Moderna will achieve revenue growth again by late 2026. The company is working toward regulatory approval for its combination flu-COVID vaccine and a standalone influenza vaccine during the current year.
Pipeline and Clinical Milestones Ahead
Multiple clinical trial outcomes in oncology and rare disease programs are anticipated throughout 2026, which William Blair analysts identified as possible “new long-term growth drivers.”
The agreement eliminates what had become a persistent concern weighing on investor sentiment. Moderna’s mRNA technology platform serves as the foundation for its expanding pipeline extending far beyond COVID-19 applications.
Both Arbutus and Genevant characterized this arrangement as the largest publicly disclosed patent settlement in pharmaceutical industry history and the second-largest settlement across all business sectors.
Genevant CEO James Heyes called it “enormously gratifying” to be recognized for the company’s contribution to pandemic response.
Moderna’s stock has climbed more than 60% during the past twelve months, substantially outpacing the S&P 500’s approximately 17% advance over the same timeframe.
The $950 million single payment is scheduled for the third quarter of 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
